Immunovia, Inc. in Marlborough received final regulatory approval to begin patient testing with a new pancreatic cancer diagnostic test, according to a press announcement on Tuesday.
The test, dubbed IMMrayTM PanCan-d, is the first and only test on the market dedicated to early detection of pancreatic cancer, said the release.
The price of the test was increased from $600 to $995, in keeping with recent studies showing economic benefits at a higher price.
Demand for pancreatic cancer testing is a growing market, with roughly 350,000 individuals seeking testing in the United States. That number is expected to grow to 1.5 million due to a national testing recommendation for patients with one or more relatives with pancreatic cancer, said Immunovia CEO Patrick Dahlen, in a statement.
Immunovia was established in Marlborough in 2017 to create blood tests for early detection of cancer and autoimmune diseases.
